StockData
Edgewise Therapeutics, Inc. logo

Edgewise Therapeutics, Inc. (EWTX) company profile

EWTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$42.04−1.64 (-3.75%)

Close on Nov 17, 2026Market cap $4.57BP/E –Yield –

About Edgewise Therapeutics

Pharmaceutical Preparations, SIC 2834

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing precision small molecule medicines for severe neuromuscular and cardiac disorders. The company utilizes a proprietary, muscle-focused drug discovery platform that evaluates integrated muscle function in whole organ extracts. Its pipeline features lead candidate sevasemten, an orally administered fast myofiber myosin inhibitor in late-stage clinical trials for Becker muscular dystrophy and Duchenne muscular dystrophy. Edgewise is also developing cardiac sarcomere modulators, including clinical-stage candidate EDG-7500 for hypertrophic cardiomyopathy and EDG-15400 for heart failure with preserved ejection fraction, along with preclinical cardiometabolic programs. Its intended customer base comprises patients affected by rare, debilitating skeletal and cardiac muscle conditions with limited or no approved therapies.

The company retains global development and commercialization rights to all its programs and plans to establish an internal commercial organization within the United States while evaluating collaborations globally. The provided excerpt contains no information regarding the company's founding year, website, or headquarters location.

Summary of the business section of Edgewise Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Edgewise Therapeutics, Inc.
Headquarters
Boulder, CO
Address
1715 38th St 80301
Phone
(720) 262-7002
Employees
146, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
KPMG LLP, Denver, Colorado

Stock & identifiers

Ticker
EWTX
Exchange
Nasdaq
IPO date
Mar 26, 2021
Shares outstanding
109M, Jul 31, 2026
Public float
$1.20B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1710072
CUSIP
28036F105
ISIN
US28036F1057
FIGI
BBG00K4Y2H24
Share class FIGI
BBG00K4Y2H33
EIN
82-1725586

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Alan J. RussellChief Scientific Officer, Director31,856
Kevin KochPresident and CEO, Director391,272
Michael NofiChief Financial Officer6,495
Behrad DerakhshanChief Business Officer29,426
John R. MooreGeneral Counsel15,995
Joanne M. DonovanCMO8,625
Robert BlausteinChief Development Officer–
R. Michael CarruthersChief Financial Officer86,162
Marc SemigranChief Development Officer6,716
Jonathan C. FoxDirector25,141
Jonathan D. RootDirector15,625
Laura BregeDirector–
Peter A. ThompsonDirector443,792
Arlene MorrisDirector–
Christopher Nathan MartinDirector–
Badreddin EdrisDirector96,760
Genesis GP LLC OrbiMedDirector14,809,075
Advisors Llc OrbimedDirector319,599
Capital GP VI LLC OrbiMedDirector14,436,497

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$7.36M$7.87M$3.32M$286$139
FY2024$7.60M$35.60M$2.91M$307$104
FY2023$3.98M$9.61M$1.74M$128$105

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Kevin Koch, Ph.D.
President and Chief Executive Officer
$670.00K$1.17M$5.04M$462.30K$14.00K$7.36M-3%
Michael P. Nofi
Chief Financial Officer
$67.81K$799.75K$3.39M$29.89K–$4.28M–
Robert Blaustein, M.D., Ph.D.
Former Chief Development Officer
$525.00K$999.48K$2.80M$227.61K$14.00K$4.57M–
R. Michael Carruthers
Former Chief Financial Officer
$465.69K$392.71K$1.50M$214.22K$14.00K$2.59M–
Behrad Derakhshan, Ph.D.
Chief Operating Officer
$520.00K$401.70K$1.73M$269.10K$14.00K$2.93M+1%
Joanne M. Donovan, M.D., Ph.D.
Chief Medical Officer
$530.36K$376.59K$1.62M$243.97K$14.00K$2.79M-5%
Alan Russell, Ph.D.
Co-Founder and Chief Scientific Officer
$499.58K$376.59K$1.62M$229.81K$8.48K$2.73M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Mar 26, 2021
Offer price
$16.00
Securities offered
11,000,000
Gross proceeds
$176.00M
Exchange
Nasdaq
First trading day
Mar 26, 2021
First-day close
$30.00+87.5%
Lock-up ends (est.)
Sep 22, 2021

“The initial public offering price is $16.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 146 full-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?